Azoles

George R. Thompson; Thomas F. Patterson

doi:10.1007/978-90-481-2408-4_15

Azoles

George R. Thompson
, Thomas F. Patterson

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

The treatment of invasive aspergillosis remains difficult and until recently only polyenes and itraconazole were viable treatment options. However the development of newer triazoles (voriconazole, posaconazole) has been a welcome addition to the antifungal armamentarium. The proven efficacy of prophylactic posaconazole in high-risk patients, and the use of voriconazole during treatment of invasive aspergillosis have largely replaced amphotericin B and itraconazole use for these indications. Other extended-spectrum triazoles in preclinical development (ravuconazole, isavuconazole, and albaconazole) offer additional pharmacodynamic/pharmacokinetic advantages and will also be reviewed.

Original language	English (US)
Title of host publication	Aspergillosis
Subtitle of host publication	From Diagnosis to Prevention
Publisher	Springer Netherlands
Pages	231-262
Number of pages	32
ISBN (Electronic)	9789048124084
ISBN (Print)	9789048124077
DOIs	https://doi.org/10.1007/978-90-481-2408-4_15
State	Published - 2010

Keywords

Albaconazole
Isavuconazole
Itraconazole
Posaconazole
Ravuconazole
Triazoles
Voriconazole

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-90-481-2408-4_15

Cite this

@inbook{b47fc9abe9e846a09bf9448ee9a46829,

title = "Azoles",

abstract = "The treatment of invasive aspergillosis remains difficult and until recently only polyenes and itraconazole were viable treatment options. However the development of newer triazoles (voriconazole, posaconazole) has been a welcome addition to the antifungal armamentarium. The proven efficacy of prophylactic posaconazole in high-risk patients, and the use of voriconazole during treatment of invasive aspergillosis have largely replaced amphotericin B and itraconazole use for these indications. Other extended-spectrum triazoles in preclinical development (ravuconazole, isavuconazole, and albaconazole) offer additional pharmacodynamic/pharmacokinetic advantages and will also be reviewed.",

keywords = "Albaconazole, Isavuconazole, Itraconazole, Posaconazole, Ravuconazole, Triazoles, Voriconazole",

author = "Thompson, \{George R.\} and Patterson, \{Thomas F.\}",

note = "Publisher Copyright: {\textcopyright} Springer Science+Business Media B.V. 2010.",

year = "2010",

doi = "10.1007/978-90-481-2408-4\_15",

language = "English (US)",

isbn = "9789048124077",

pages = "231--262",

booktitle = "Aspergillosis",

publisher = "Springer Netherlands",

}

TY - CHAP

T1 - Azoles

AU - Thompson, George R.

AU - Patterson, Thomas F.

N1 - Publisher Copyright: © Springer Science+Business Media B.V. 2010.

PY - 2010

Y1 - 2010

N2 - The treatment of invasive aspergillosis remains difficult and until recently only polyenes and itraconazole were viable treatment options. However the development of newer triazoles (voriconazole, posaconazole) has been a welcome addition to the antifungal armamentarium. The proven efficacy of prophylactic posaconazole in high-risk patients, and the use of voriconazole during treatment of invasive aspergillosis have largely replaced amphotericin B and itraconazole use for these indications. Other extended-spectrum triazoles in preclinical development (ravuconazole, isavuconazole, and albaconazole) offer additional pharmacodynamic/pharmacokinetic advantages and will also be reviewed.

AB - The treatment of invasive aspergillosis remains difficult and until recently only polyenes and itraconazole were viable treatment options. However the development of newer triazoles (voriconazole, posaconazole) has been a welcome addition to the antifungal armamentarium. The proven efficacy of prophylactic posaconazole in high-risk patients, and the use of voriconazole during treatment of invasive aspergillosis have largely replaced amphotericin B and itraconazole use for these indications. Other extended-spectrum triazoles in preclinical development (ravuconazole, isavuconazole, and albaconazole) offer additional pharmacodynamic/pharmacokinetic advantages and will also be reviewed.

KW - Albaconazole

KW - Isavuconazole

KW - Itraconazole

KW - Posaconazole

KW - Ravuconazole

KW - Triazoles

KW - Voriconazole

UR - https://www.scopus.com/pages/publications/84919687646

UR - https://www.scopus.com/pages/publications/84919687646#tab=citedBy

U2 - 10.1007/978-90-481-2408-4_15

DO - 10.1007/978-90-481-2408-4_15

M3 - Chapter

AN - SCOPUS:84919687646

SN - 9789048124077

SP - 231

EP - 262

BT - Aspergillosis

PB - Springer Netherlands

ER -

Azoles

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this